HK Stock Market Move | JACOBIO-B(01167) rose more than 16% after its performance, Golersei received approval for listing, and the company's mid-term revenue increased to 45.7 million yuan.

JACOBIO-B (01167) surged more than 16% after the results, closing at a 16.52% increase to HKD 9.45, with a turnover of HKD 97.6885 million. On the news front, JACOBIO released its interim results, with the group achieving RMB 45.664 million in the period, compared to zero revenue in the same period last year; the company's attributable loss was RMB 58.994 million, a 65.1% improvement year-on-year. The revenue growth was mainly due to milestone payments from the licensing agreement with Shanghai Allist Pharmaceuticals Co., Ltd. In addition, the company's clinical candidate drug JAB-BX467 for HER2-STING iADC was nominated in the second half of 2024 and planned to submit an IND application in 2026. Public information shows that in August 2024, Shanghai Allist Pharmaceuticals Co., Ltd. introduced the KRAS G12C inhibitor product Golarecera from JACOBIO, primarily used for the treatment of advanced solid tumors in patients with the KRAS G12C mutation. Shanghai Allist Pharmaceuticals Co., Ltd. has exclusive rights for research, development, production, registration, and commercialization of the product in China. In the half-year report, Golarecera has officially started the commercialization process and issued the first prescription in multiple locations nationwide in June 2025. In May 2025, Golarecera obtained approval from the National Medical Products Administration for the treatment of adult patients with advanced non-small cell lung cancer with at least one systemic treatment and the KRAS G12C mutation.